Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

被引：0
|
作者：
Yoshiteru Takekita
Yosuke Koshikawa
Chiara Fabbri
Shiho Sakai
Naotaka Sunada
Ai Onohara
Keiichiro Nishida
Masafumi Yoshimura
Masaki Kato
Alessandro Serretti
Toshihiko Kinoshita
机构：
[1] University of Bologna,Department of Biomedical and NeuroMotor Sciences
[2] Kansai Medical University,Department of Neuropsychiatry
来源：
BMC Psychiatry | / 16卷
关键词：
Schizophrenia; Risperidone long-acting injection; Paliperidone palmitate; Cognitive function; Efficacy; Subjective well-being;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] AN OPEN, RANDOMIZED, CONTROLLED COMPARISON OF LONG-ACTING INJECTABLE RISPERIDONE VS. ORAL OLANZAPINE IN SCHIZOPHRENIA & SCHIZOAFFECTIVE DISORDER
    Keks, Nicholas A.
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S5 - S5
  • [32] Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial
    Covell, Nancy H.
    McEvoy, Joseph P.
    Schooler, Nina R.
    Stroup, T. Scott
    Jackson, Carlos T.
    Rojas, Ingrid A.
    Essock, Susan M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (05) : 669 - 675
  • [33] The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: A preliminary open-label trial
    Suzuki, Hidenobu
    Gen, Keishi
    Inoue, Yuichi
    Hibino, Hiroyuki
    Mikami, Ayako
    Matsumoto, Hideo
    Mikami, Katsunaka
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2014, 18 (01) : 58 - 62
  • [34] Risperidone long-acting injectable for maintenance therapy in bipolar disorder:: An open-label pilot study
    Braeunig, Peter
    Sacchett, Emilio
    Medori, Rossella
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (01) : 74 - 77
  • [35] Descriptive study of 100 patients with a diagnosis of psychosis treated with Paliperidone Palmitate 6-Month Long-Acting Injectable.
    Mesones, J.
    Miller, A.
    Bautista, N.
    Dieguez, J.
    Calero, I.
    Grinant, A.
    EUROPEAN PSYCHIATRY, 2024, 67 : S387 - S387
  • [36] Bioequivalence of paliperidone long acting injection in patients with schizophrenia: results from a randomized, cross-over, open-label study
    Shetty, Arthik
    Chakra, Amaresh
    Shah, Chirayu
    Devkare, Prashant
    Dharmadhikari, Shruti
    Mane, Amey
    Mehta, Suyog
    INDIAN JOURNAL OF PSYCHIATRY, 2024, 66 : S175 - S175
  • [37] A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder
    Yatham, L. N.
    Fallu, A.
    Binder, C. E.
    ACTA PSYCHIATRICA SCANDINAVICA, 2007, 116 : 50 - 56
  • [38] An open-label trial of risperidone long-acting injectable in the treatment of subject with recent onset psychosis
    Emsley, R.
    Schreiner, A.
    Koen, L.
    Oosthuizen, P.
    Niehaus, D.
    Rabinowitz, J.
    EARLY INTERVENTION IN PSYCHIATRY, 2008, 2 : A100 - A100
  • [39] A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea
    Lee, Nam Young
    Kim, Se Hyun
    Cho, Seong Jin
    Chung, Young-Cho
    Jung, In Kwa
    Kim, Chang Yoon
    Kim, Duk Ho
    Lee, Dong Geun
    Lee, Yo Han
    Lim, Weon Jeong
    Na, Young Suk
    Shin, Sang Eun
    Woo, Jong-Min
    Yoon, Jin Sang
    Yoon, Bo-Hyun
    Ahn, Yong Min
    Kim, Yong Sik
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (05) : 279 - 287
  • [40] Paliperidone palmitate 6-month long-acting injectable for schizophrenia: A randomised, double-blind, multi-center, noninferiority phase 3 study
    Najarian, D.
    Sanga, P.
    Wang, S.
    Lim, P.
    Singh, A.
    Robertson, M. J.
    Cohen, K.
    Schotte, A.
    Milz, R.
    Venkatasubramanian, R.
    T'Jollyn, H.
    Walling, D. P.
    Galderisi, S.
    Gopal, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S393 - S393
12345